Skip to main content
Clinical Trials/NCT05761652
NCT05761652
Recruiting
Not Applicable

An Early Warning Model for Assessing the Onset, Progression and Sequelae of COVID-19

Xiyuan Hospital of China Academy of Chinese Medical Sciences1 site in 1 country378 target enrollmentDecember 1, 2022
ConditionsCOVID-19

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
COVID-19
Sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Enrollment
378
Locations
1
Primary Endpoint
TCM based Evaluation:
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

Based on the characteristics of symptoms, differences in physical and chemical examinations and tests, and characteristics of traditional Chinese medicine (TCM) disease differentiation and syndrome differentiation, the evaluation indicators for the clinical early warning model were screened, and the "three-level early warning mechanism for COVID-19 patients at high risks, with progression to severe cases and sequelae was constructed.

Detailed Description

Adopt multi-level evidence base architecture, build "multi-source data analysis, feature extraction, multi-level evidence extraction, active The integrated Chinese and Western medicine big data platform integrates the original evidence processing into a multi-level evidence base, comprehensive analysis of The platform will generate a multi-level evidence base by processing the original evidence, analyze the evaluation indexes of New Coronary Pneumonia, select the features, build a deep neural network model, train and validate the model, and establish a high The model is trained and validated, and a three-level early warning model is established for people at high risk of new coronary pneumonia, those who turn serious, and those with sequelae.

Registry
clinicaltrials.gov
Start Date
December 1, 2022
End Date
June 1, 2024
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Meeting the diagnostic criteria of mild and moderate types of COVID-19 disease described in the "Diagnostic and Treatment Protocol for Novel Coronavirus Pneumonia (Trial version 9)" \[9\];
  • Age ≥18 years old and ≤90years old;
  • Not more than 5 days after the occurrence of the first symptom (or confirmed onset);
  • The subject agrees to participate the study and have signed the informed consent form by paper signature, electronic signature of mobile software or voice authorization.

Exclusion Criteria

  • Pregnant or lactating women;
  • Patients complicated with severe heart, liver, kidney, blood system and other primary diseases and mental disorders.
  • Patients with disturbance of consciousness, aphasia, dementia and other conditions that prevent them from cooperating with the clinical investigators
  • Patients with incomplete study data.

Outcomes

Primary Outcomes

TCM based Evaluation:

Time Frame: Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

TCM constitution differentiation With reference to the Classification and Determination of Constitutions in TCM issued by the China Association of Traditional Chinese Medicine. There are nine constitution types based on TCM syndrome differentiation

General Data:

Time Frame: Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

including age, underlying diseases, body weight, occupation, smoking, alcohol drinking, salt intake and exercise

Environment Indicators:

Time Frame: Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

air temperature, humidity, and air quality

Auxiliary Examination Indicators:

Time Frame: Not more than 5 days after the occurrence of the first symptom (or confirmed onset)

blood routine (lymphocyte count, lymphocyte/neutrophil ratio), four coagulation items (PT, APTT, TT, FIB), D-Di, C-reactive protein, erythrocyte sedimentation rate, liver function (ALT, AST, ALP), renal function (BUN, Cr), blood glucose, lung CT

Study Sites (1)

Loading locations...

Similar Trials